HISTOACRYL® Used for Embolization of Thoracoabdominal Artery Bleeding

This observational study will collect information from adult patients in Japan who are treated with Histoacryl® to stop bleeding from arteries in the chest or abdomen, in order to better understand how well the treatment works and how safe it is during routine medical care.

Inclusion Criteria: * Active thoracoabdominal arterial bleeding diagnosed by endoscopy, catheter angiography, or computed tomography angiography (CTA). * Planned embolization treatment using Histoacryl® as the sole embolic agent for the target lesion. * No endoleak following thoracic endovascular aortic repair (TEVAR) or endovascular abdominal aortic repair (EVAR). * Patients with malignant tumors must have an expected survival of at least 1 month. * Written informed consent obtained from the patient or a legally authorized representative. Exclusion Criteria: * Previous embolization in the target vascular territory. * Known allergy or hypersensitivity to n-butyl cyanoacrylate (NBCA), Lipiodol®, or related treatment components. * Use of adjunctive embolic agents in the same target location. * Planned surgical treatment after embolization as part of a predefined two-step treatment strategy. * Severe septicemia. * Participation in another clinical trial. * Target vessels unsuitable for safe Histoacryl® injection. * Empiric embolization without identification of a target bleeding location. * Pregnancy, with the exception of patients treated for postpartum hemorrhage.